Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent, Inc.(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference onTuesday, January 13, 2026, at9:00 a.m. PTin San Francisco. https://mma.prnewswire.com/media/1583941/Nuvalent_Inc_Logo_2024.jpg A live webcast will be available in the […]